P0170 Trastuzumab for HER2-positive breast cancer: Experience from a middle-income Asian country

• Published in: European journal of cancer (1990) 2015-07, Vol.51, p.e32-e33
• Main Authors: Ho, G.F, Mastura, M.Y, Kaur, R.P, Hoo, L.P, Lim, T.O
• Format: Article
• Language: English
• Subjects: Hematology, Oncology and Palliative Medicine
• ISSN: 0959-8049; 1879-0852
• DOI: 10.1016/j.ejca.2015.06.096

Background Trastuzumab has been available in Malaysia for 20 years. However, the vast majority of patients, even those with stage I–III disease, have limited access to the treatment. This could be because, in the absence of a reliable registry, policy makers and health professionals are ill informed of the poor survival outcome in the local population and the potential effect of modern therapies to improve outcome. Patients would naturally seek treatment when they could afford to pay for it, thus creating a natural experiment to explore the effect of trastuzumab in this population. Methods We identified 189 HER2-positive breast cancer patients with sufficient data from a cohort previously enrolled in an observational study to evaluate cancer care performance in 2011–12. 39 (21%) of these patients were treated with trastuzumab while 150 (79%) were not. We use Cox proportional hazards model to estimate the effect of trastuzumab on overall survival. Prognostic covariates included were age, stage, and tumour size. Findings The median age of the patients was 52 years; 36% was aged